Current status and challenges in HER2 IHC assessment: scoring survey results in Japan
Open Access
- 4 November 2024
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 210 (1) , 27-36
Abstract
Purpose This study aimed to assess the concordance of human epidermal growth factor receptor 2 (HER2) expression scoring by immunohistochemistry (IHC) among practicing pathologists in Japan, given the challenging nature of scoring and the critical role of HER2 status in breast cancer management. Methods Whole slide images (WSI) from 20 invasive breast cancer cases (1 representative WSI per case) selected to represent a diverse IHC scores and staining patterns were used in an online survey involving seven reference pathologists who established consensus HER2 IHC scores (0 to 3 +) decided by majority interpretation. Participating pathologists nationwide scored the same 20 WSI cases online using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2018 guidelines. Deidentified case metadata were registered in the uPath system. Results A total of 144 participating pathologists responded. The scoring results of the participating pathologists most commonly agreed with the consensus IHC score, followed by a ± 1 point deviation and no survey responses with > 1 point deviation. The mean percentage of agreement with the consensus score for all 20 cases was 63.4%. In cases where the reference pathologists' scores were discordant, the participating pathologists also showed a lower concordance rate. Conclusion This study highlighted the current status of HER2 expression scoring by IHC for breast cancer among pathologists in Japan. These findings underscore the challenges in HER2 IHC scoring cases and emphasize the need for improved standardization and training, especially in the evolving landscape of HER2-targeted therapies.Keywords
This publication has 32 references indexed in Scilit:
- Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice GuidelinesBreast Cancer, 2024
- The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 editionBreast Cancer, 2023
- Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathologyThe Breast, 2023
- Multi-institutional Assessment of Pathologist Scoring HER2 ImmunohistochemistryLaboratory Investigation, 2023
- HER2-low breast cancer: Novel detections and treatment advancesCritical Reviews in Oncology/Hematology, 2022
- LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trialAnnals of Oncology, 2022
- Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyondSeminars in Cancer Biology, 2021
- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancernpj Breast Cancer, 2021
- Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 yearsLaboratory Investigation, 2018
- Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17Cancer, 2010